Cancer Biopsy Market Size, Share, and Trends 2024 to 2034

Cancer Biopsy Market Size to Worth USD 172.29 Bn by 2034

The global cancer biopsy market size was USD 25.90 billion in 2023, accounted for USD 30.77 billion in 2024, and is expected to reach around USD 172.29 billion by 2034, expanding at a CAGR of 18.8% from 2024 to 2034. The North America cancer biopsy market size reached USD 10.62 billion in 2023.

Cancer Biopsy Market Key Takeaways

• North America led the global market with the highest market share of 47% in 2023.
• By type, the tissue biopsy segment is estimated to capture the biggest revenue share in 2023.
• By type, the liquid biopsy segment is anticipated to grow at a remarkable CAGR between 2024 and 2034.
• By product, the kits and consumables segment predicted to register the maximum market share of 61% in 2023.
• By application, the breast cancer segment is estimated to hold the highest market share in 2023.

U.S. Cancer Biopsy Market Size and Growth 2024 to 2034

The U.S. cancer biopsy market size was estimated at USD 7.45 billion in 2023 and is predicted to be worth around USD 50.60 billion by 2034, at a CAGR of 19% from 2024 to 2034.

North America dominated the cancer biopsy market in 2023. The North America region is expected to maintain its lead during the projected period, with the U.S. contributing significantly to regional revenue. Furthermore, distributors and manufacturers in this region are working to sale and manufacture unique kits that are well-suited for quick diagnostic applications.  

Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. The number of lung cancer cases detected in Asia has increased due to rising awareness among patients and healthcare professionals.

Cancer Biopsy Market Growth Factors

The removal of tissue for the purpose of examining it for disease is known as a biopsy. Any region of the body can be used to collect tissue samples. Biopsies can be done in a variety of methods. Some biopsies entail taking a little bit of tissue with a needle, while others entail surgically removing a suspected lump or nodule. The imaging tests like MRIs and CT scans can assist detect lumps or abnormal tissue, but they cannot distinguish the difference between cancerous and non-cancerous cells. The only approach to diagnose most malignancies is to take a biopsy and collect cells for further analysis.

The growing elderly population, together with the rising prevalence of cancer indications, is likely to drive the cancer biopsy market expansion. Furthermore, the introduction of liquid biopsy procedures is projected to boost the cancer biopsy market forward. In the field of oncology diagnostics, many procedures such as skin, needle, bone marrow, endoscopic, and surgical biopsies are used on a large scale. The needles biopsies are regarded a favored tool for early detection of patients among these techniques. However, benefits of fine needle aspiration needle biopsies, such as reduced invasion and faster results, have the cancer biopsy market expansion.

The liquid biopsy for cancer diagnosis, prognosis, screening, and treatment has increased competition and capabilities in the cancer biopsy market significantly. The key market players are taking significant steps to enter the cancer biopsy market and are conducting liquid biopsies, which are projected to drive the cancer biopsy market’s growth in clinical settings. The liquid biopsy is being utilized to diagnose advanced cancer in individuals who are unable to undergo a tissue biopsy.

The liquid biopsy can also be used to determine targeted therapy or clinical trial eligibility for patients for whom tissue-based testing is not appropriate or available. The liquid biopsy provides oncologists with real-time information about a tumor and is a quick, minimally invasive, and cost-effective diagnostic. These tests have the potential to reveal residual tumor cells, early recurrence diagnosis, and treatment efficacy.

While the issues connected with cancer biopsy pose significant obstacles for technology vendors, laboratories, and clinicians, patients who want to avoid the genuine hazards, potential pain, and high costs associated with tissue biopsy have a strong demand for liquid biopsy. Furthermore, the ability to track treatments and detect disorder early, as well as collect data across the tumor, gives patients a better chance of receiving appropriately targeted therapy.

In terms of instruments, kits, and consumables, cancer biopsy has seen a number of technological advancements. The development of effective products associated with biopsies is critical as liquid biopsy becomes a multimodal tool of diagnosis in the field of clinical oncology. Despite the fact that existing instruments are widely utilized, they have a number of flaws. The introduction of new technologies, on the other hand, is predicted to dramatically enhance the need for instruments in the coming years. Several new companies are concentrating on developing equipment that can improve endoscopy-based biopsies.

Market Scope

Type Insights

The tissue biopsy had the highest revenue share in 2023. It is still widely used in biopsies and is widely used across a variety of cancer diagnosis applications. This is due to the rigorous research operations testing its safety and efficacy, which have helped to the expansion of this segment.

The liquid biopsy segment is fastest growing segment of the cancer biopsy market in 2023. In recent years, there has been an increase in physician preference for liquid biopsy, which is bolstered by its capacity to provide disease assessments from both the primary and distant tumor locations. This method is used in personalized medicine treatment, where tumor makers are sampled regularly to adjust the treatment based on the patient’s response. 

Product Insights

The kits and consumables segment dominated the cancer biopsy market in 2023. The segment’s expansion has been aided significantly by large investments made by major market players in the industry.

The instruments segment, on the other hand, is predicted to develop at a rapid rate over the projection period. The rise of the market is related to an increase in the number of patients around the world who require precise, efficient, and quick tools and kits.

Application Insights

In 2023, the breast cancer segment dominated the cancer biopsy market. The growing number of patients suspected of having breast cancer undergoes microscopic study of breast tissue, which is required for obtaining a clear diagnosis, as well as determining the stage and type.

The prostate cancer segment, on the other hand, is predicted to develop at the quickest rate in the future years. The liquid biopsies based on circulating tumor cells can track the minimal residual disease in non-metastatic prostate cancer patients, as well as the follow up examinations, to provide independent prognostic insights.

Cancer Biopsy Market Companies

• Myriad Genetics Inc.
• Guardant Health Inc.
• Exact Sciences Corporation
• Bio-Rad Laboratories Inc.
• Agena Bioscience Inc.
• Personal Genome Diagnostics Inc.
• Exosome Diagnostics Inc.
• ANGLE Plc.
• F. Hoffmann-La Roche Ltd.

Recent Developments

• Guardant Health Inc. and MD Anderson established an agreement in January 2017 to make complete liquid biopsy a standard of care in cancer.
• Illumina Inc. reported in March 2021 that their NextSeq 550Dx platform and accompanying reagent kits had received medical device registration in Russia. Prior to this registration, the MiSeq Dx had already been approved as a medical device.

Segments Covered in the Report

By Product

• Instruments
• Kits and Consumables
• Services

By Type

• Tissue Biopsies
  • Fine Needle Aspiration (FNA)
  • Core Needle Biopsy (CNB)
• Needle Biopsies
• Surgical Biopsies
• Liquid Biopsies
• Others

By Application

• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Lung Cancer
• Prostate Cancer
• Skin Cancer
• Blood Cancer
• Kidney Cancer
• Liver Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • U.K.
  • Germany
  • France
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa